KFAS
CLB icon

Keating Financial Advisory Services’s Core Laboratories CLB Stock Holding History

Keating Financial Advisory Services’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$419 Sell
36
-16
-31% -$228 ﹤0.01% 2363
2026
Q1 		$873 Buy
+52
New +$930 ﹤0.01% 2123

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Keating Financial Advisory Services's CLB Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its Core Laboratories (CLB) stake by 31% in Q2 2026, selling an estimated $228 and leaving 36 shares worth $419. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

Keating Financial Advisory Services first reported a position in CLB in Q1 2026 and has held it in 2 quarters since. The position peaked at $873 in Q1 2026. 186 funds tracked by Wall St. Rank hold CLB as of Q2 2026.

  • Keating Financial Advisory Services held 36 shares of Core Laboratories worth $419 as of Q2 2026.
  • Keating Financial Advisory Services sold 16 Core Laboratories shares in Q2 2026, an estimated $228.
  • Core Laboratories made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2363 holding.
  • Keating Financial Advisory Services first reported a position in Core Laboratories in Q1 2026 and has held it in 2 quarters since.
  • Keating Financial Advisory Services's Core Laboratories position peaked at $873 in Q1 2026.
  • 186 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.